Cerebellum’s Amgen AMGN Stock Holding History

Cerebellum’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,961	Closed	-$167K	–	418
2018 Q2	$167K	Buy	+1,961	New	+$347K	0.28%	282

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cerebellum's AMGN Position: Q3 2018 in Review

Cerebellum sold out of Amgen (AMGN) in Q3 2018, closing a stake of 1,961 shares — an estimated $167K sold.

Cerebellum first reported a position in AMGN in Q2 2018 and held it in 1 quarter. The position peaked at $167K in Q2 2018. 1,796 funds tracked by Wall St. Rank hold AMGN as of Q3 2018.

Cerebellum reported no remaining Amgen position as of Q3 2018 after selling out during the quarter.
Cerebellum sold 1,961 Amgen shares in Q3 2018, an estimated $167K.
Cerebellum first reported a position in Amgen in Q2 2018 and held it in 1 quarter.
Cerebellum's Amgen position peaked at $167K in Q2 2018.
1,796 funds tracked by Wall St. Rank held Amgen as of Q3 2018.

Based on Cerebellum's 13F filing for Q3 2018, filed 9 Oct 2018.